Which has preferable earnings & valuation, EHC or MEDP?

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Encompass Health $6.07B 1.81 $566.20M $5.99 18.48 Medpace $2.53B 6.38 $451.12M $17.06 33.90

Does the media favor EHC or MEDP?

In the previous week, Medpace had 21 more articles in the media than Encompass Health. MarketBeat recorded 38 mentions for Medpace and 17 mentions for Encompass Health. Encompass Health's average media sentiment score of 1.35 beat Medpace's score of 0.97 indicating that Encompass Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Encompass Health 15 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 24 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ELV or MEDP?

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elevance Health $199.13B 0.41 $5.66B $22.50 16.70 Medpace $2.53B 6.38 $451.12M $17.06 33.90

Is ELV or MEDP more profitable?

Medpace has a net margin of 17.67% compared to Elevance Health's net margin of 2.47%. Medpace's return on equity of 110.15% beat Elevance Health's return on equity. Company Net Margins Return on Equity Return on Assets Elevance Health 2.47% 14.64% 5.22% Medpace 17.67% 110.15% 24.84%

Does the media favor ELV or MEDP?

In the previous week, Elevance Health had 3 more articles in the media than Medpace. MarketBeat recorded 41 mentions for Elevance Health and 38 mentions for Medpace. Elevance Health's average media sentiment score of 1.12 beat Medpace's score of 0.97 indicating that Elevance Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elevance Health 25 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 24 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, MEDP or HIMS?

Medpace has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.38 $451.12M $17.06 33.90 Hims & Hers Health $2.35B 2.68 $128.37M -$0.09 N/A

Does the media favor MEDP or HIMS?

In the previous week, Medpace had 9 more articles in the media than Hims & Hers Health. MarketBeat recorded 38 mentions for Medpace and 29 mentions for Hims & Hers Health. Medpace's average media sentiment score of 0.97 beat Hims & Hers Health's score of 0.37 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 24 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 7 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings and valuation, IQV or MEDP?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.98B 2.34 $1.36B $8.06 29.60 Medpace $2.53B 6.38 $451.12M $17.06 33.90

Is IQV or MEDP more profitable?

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.10% 30.25% 6.54% Medpace 17.67% 110.15% 24.84%

Does the media favor IQV or MEDP?

In the previous week, IQVIA had 12 more articles in the media than Medpace. MarketBeat recorded 50 mentions for IQVIA and 38 mentions for Medpace. Medpace's average media sentiment score of 0.97 beat IQVIA's score of 0.96 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 22 Very Positive mention(s) 7 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 24 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MEDP or RELX?

Medpace currently has a consensus target price of $584.18, suggesting a potential upside of 1.02%. Given Medpace's higher probable upside, analysts plainly believe Medpace is more favorable than Relx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medpace 0 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.15 Relx 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has stronger earnings & valuation, MEDP or RELX?

Relx has higher revenue and earnings than Medpace. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.38 $451.12M $17.06 33.90 Relx $12.64B 5.08 $2.72B N/A N/A

Is MEDP or RELX more profitable?

Medpace has a net margin of 17.67% compared to Relx's net margin of 0.00%. Medpace's return on equity of 110.15% beat Relx's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% Relx N/A N/A N/A

Does the media refer more to MEDP or RELX?

In the previous week, Medpace had 27 more articles in the media than Relx. MarketBeat recorded 38 mentions for Medpace and 11 mentions for Relx. Medpace's average media sentiment score of 0.97 beat Relx's score of 0.94 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 24 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Relx 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Medpace (MEDP) Competitors

$578.30 -6.63 (-1.13%)

Closing price 07/30/2026 04:00 PM Eastern

Extended Trading

$575.62 -2.68 (-0.46%)

As of 04:29 AM Eastern

Compare

MEDP vs. EHC, ELV, HIMS, IQV, and RELX

Should you buy Medpace stock or one of its competitors? MarketBeat compares Medpace with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medpace include Encompass Health (EHC), Elevance Health (ELV), Hims & Hers Health (HIMS), IQVIA (IQV), and Relx (RELX).

How does Medpace compare to Encompass Health?

Encompass Health (NYSE:EHC) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, Medpace had 21 more articles in the media than Encompass Health. MarketBeat recorded 38 mentions for Medpace and 17 mentions for Encompass Health. Encompass Health's average media sentiment score of 1.35 beat Medpace's score of 0.97 indicating that Encompass Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Encompass Health	15 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	24 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Encompass Health has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Encompass Health currently has a consensus target price of $143.86, indicating a potential upside of 29.94%. Medpace has a consensus target price of $584.18, indicating a potential upside of 1.02%. Given Encompass Health's stronger consensus rating and higher probable upside, analysts plainly believe Encompass Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Encompass Health	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
Medpace	0 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.15

97.3% of Encompass Health shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 1.8% of Encompass Health shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Encompass Health	$6.07B	1.81	$566.20M	$5.99	18.48
Medpace	$2.53B	6.38	$451.12M	$17.06	33.90

Medpace has a net margin of 17.67% compared to Encompass Health's net margin of 10.04%. Medpace's return on equity of 110.15% beat Encompass Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Encompass Health	10.04%	18.28%	8.27%
Medpace	17.67%	110.15%	24.84%

Summary

Medpace beats Encompass Health on 9 of the 17 factors compared between the two stocks.

How does Medpace compare to Elevance Health?

Elevance Health (NYSE:ELV) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elevance Health	$199.13B	0.41	$5.66B	$22.50	16.70
Medpace	$2.53B	6.38	$451.12M	$17.06	33.90

Medpace has a net margin of 17.67% compared to Elevance Health's net margin of 2.47%. Medpace's return on equity of 110.15% beat Elevance Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elevance Health	2.47%	14.64%	5.22%
Medpace	17.67%	110.15%	24.84%

89.2% of Elevance Health shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.3% of Elevance Health shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Elevance Health has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

In the previous week, Elevance Health had 3 more articles in the media than Medpace. MarketBeat recorded 41 mentions for Elevance Health and 38 mentions for Medpace. Elevance Health's average media sentiment score of 1.12 beat Medpace's score of 0.97 indicating that Elevance Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elevance Health	25 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	24 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Elevance Health presently has a consensus price target of $440.90, indicating a potential upside of 17.35%. Medpace has a consensus price target of $584.18, indicating a potential upside of 1.02%. Given Elevance Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Elevance Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elevance Health	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.65
Medpace	0 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.15

Summary

Elevance Health beats Medpace on 9 of the 16 factors compared between the two stocks.

How does Medpace compare to Hims & Hers Health?

Medpace (NASDAQ:MEDP) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Medpace has a net margin of 17.67% compared to Hims & Hers Health's net margin of -0.56%. Medpace's return on equity of 110.15% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Hims & Hers Health	-0.56%	6.10%	1.52%

Medpace currently has a consensus target price of $584.18, indicating a potential upside of 1.02%. Hims & Hers Health has a consensus target price of $31.43, indicating a potential upside of 15.84%. Given Hims & Hers Health's stronger consensus rating and higher possible upside, analysts clearly believe Hims & Hers Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.15
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

In the previous week, Medpace had 9 more articles in the media than Hims & Hers Health. MarketBeat recorded 38 mentions for Medpace and 29 mentions for Hims & Hers Health. Medpace's average media sentiment score of 0.97 beat Hims & Hers Health's score of 0.37 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	24 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	7 Very Positive mention(s)	2 Positive mention(s)	12 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

Medpace has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

Medpace has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.38	$451.12M	$17.06	33.90
Hims & Hers Health	$2.35B	2.68	$128.37M	-$0.09	N/A

78.0% of Medpace shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Medpace beats Hims & Hers Health on 12 of the 16 factors compared between the two stocks.

How does Medpace compare to IQVIA?

IQVIA (NYSE:IQV) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Medpace has a net margin of 17.67% compared to IQVIA's net margin of 8.10%. Medpace's return on equity of 110.15% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Medpace	17.67%	110.15%	24.84%

IQVIA has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

In the previous week, IQVIA had 12 more articles in the media than Medpace. MarketBeat recorded 50 mentions for IQVIA and 38 mentions for Medpace. Medpace's average media sentiment score of 0.97 beat IQVIA's score of 0.96 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	22 Very Positive mention(s)	7 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	24 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 1.7% of IQVIA shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.98B	2.34	$1.36B	$8.06	29.60
Medpace	$2.53B	6.38	$451.12M	$17.06	33.90

IQVIA currently has a consensus price target of $241.88, indicating a potential upside of 1.40%. Medpace has a consensus price target of $584.18, indicating a potential upside of 1.02%. Given IQVIA's stronger consensus rating and higher possible upside, equities analysts clearly believe IQVIA is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.81
Medpace	0 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.15

Summary

IQVIA and Medpace tied by winning 8 of the 16 factors compared between the two stocks.

How does Medpace compare to Relx?

Medpace (NASDAQ:MEDP) and Relx (NYSE:RELX) are both large-cap business services companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Medpace currently has a consensus target price of $584.18, suggesting a potential upside of 1.02%. Given Medpace's higher probable upside, analysts plainly believe Medpace is more favorable than Relx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.15
Relx	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Medpace has a net margin of 17.67% compared to Relx's net margin of 0.00%. Medpace's return on equity of 110.15% beat Relx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Relx	N/A	N/A	N/A

In the previous week, Medpace had 27 more articles in the media than Relx. MarketBeat recorded 38 mentions for Medpace and 11 mentions for Relx. Medpace's average media sentiment score of 0.97 beat Relx's score of 0.94 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	24 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Relx	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relx has higher revenue and earnings than Medpace.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.38	$451.12M	$17.06	33.90
Relx	$12.64B	5.08	$2.72B	N/A	N/A

78.0% of Medpace shares are owned by institutional investors. Comparatively, 15.0% of Relx shares are owned by institutional investors. 20.5% of Medpace shares are owned by insiders. Comparatively, 0.0% of Relx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Relx has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Summary

Medpace beats Relx on 10 of the 15 factors compared between the two stocks.

Get Medpace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MEDP vs. The Competition

Export

Metric	Medpace	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.33B	$9.64B	$7.04B	$12.02B
Dividend Yield	N/A	1.57%	2.65%	10.11%
P/E Ratio	33.90	26.03	27.65	23.56
Price / Sales	6.38	18.80	490.18	77.94
Price / Cash	34.38	135.30	51.74	58.30
Price / Book	37.21	6.13	10.05	5.85
Net Income	$451.12M	$179.69M	$3.60B	$336.53M
7 Day Performance	-3.84%	-0.43%	0.67%	0.38%
1 Month Performance	9.36%	-1.91%	-3.28%	-4.97%
1 Year Performance	35.37%	16.43%	24.49%	17.95%

Medpace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MEDP Medpace	2.2648 of 5 stars	$578.30 -1.1%	$584.18 +1.0%	+32.1%	$16.33B	$2.53B	33.90	6,200	Insider Trade
EHC Encompass Health	4.6869 of 5 stars	$113.77 +0.8%	$143.86 +26.4%	+0.6%	$11.20B	$5.94B	18.99	42,000	Positive News Upcoming Earnings
ELV Elevance Health	4.8979 of 5 stars	$378.17 +0.1%	$440.90 +16.6%	+27.8%	$81.91B	$199.13B	16.81	97,100	Trending News Analyst Revision
HIMS Hims & Hers Health	3.2193 of 5 stars	$30.23 +7.6%	$31.43 +4.0%	-58.6%	$6.50B	$2.35B	N/A	2,442	Trending News
IQV IQVIA	2.4785 of 5 stars	$212.76 +2.3%	$225.71 +6.1%	+24.6%	$34.72B	$16.31B	26.36	93,000	Trending News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MEDP) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and RELX

How does Medpace compare to Encompass Health?

Summary

How does Medpace compare to Elevance Health?

Summary

How does Medpace compare to Hims & Hers Health?

Summary

How does Medpace compare to IQVIA?

Summary

How does Medpace compare to Relx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and RELX

How does Medpace compare to Encompass Health?

Does the media favor EHC or MEDP?

Which has more volatility & risk, EHC or MEDP?

Do analysts recommend EHC or MEDP?

Do insiders and institutionals believe in EHC or MEDP?

Which has preferable earnings & valuation, EHC or MEDP?

Is EHC or MEDP more profitable?

Summary

How does Medpace compare to Elevance Health?

Which has stronger earnings and valuation, ELV or MEDP?

Is ELV or MEDP more profitable?

Do insiders & institutionals believe in ELV or MEDP?

Which has more volatility and risk, ELV or MEDP?

Does the media favor ELV or MEDP?

Do analysts recommend ELV or MEDP?

Summary

How does Medpace compare to Hims & Hers Health?

Is MEDP or HIMS more profitable?

Do analysts prefer MEDP or HIMS?

Does the media favor MEDP or HIMS?

Which has more risk & volatility, MEDP or HIMS?

Which has higher valuation and earnings, MEDP or HIMS?

Do institutionals and insiders believe in MEDP or HIMS?

Summary

How does Medpace compare to IQVIA?

Is IQV or MEDP more profitable?

Which has more risk & volatility, IQV or MEDP?

Does the media favor IQV or MEDP?

Do institutionals & insiders hold more shares of IQV or MEDP?

Which has higher earnings and valuation, IQV or MEDP?

Do analysts rate IQV or MEDP?

Summary

How does Medpace compare to Relx?

Do analysts prefer MEDP or RELX?

Is MEDP or RELX more profitable?

Does the media refer more to MEDP or RELX?

Which has stronger earnings & valuation, MEDP or RELX?

Do institutionals and insiders have more ownership in MEDP or RELX?

Which has more risk & volatility, MEDP or RELX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools